Inflammatory Bowel Disease: Basic Research, Clinical Implications and Trends in TherapyL.R. Sutherland The inflammatory bowel diseases, of unknown etiology and for which there are no cures, continue to attract the attention and interest of gastroenterologists, internists and surgeons. International symposia are common and it is safe to say that there is at least one major symposium held somewhere in the world each year. This book encompasses the proceedings of two recent symposia held in Victoria, British Columbia, Canada. The symposia were the fifth and sixth international meetings focused on inflammatory bowel disease in Canada in the last eight years. Once again they were sponsored by Axcan Pharma, Inc. (formerly Interfalk Canada, Inc.) and endorsed by the Canadian Association of Gastroenterology. As has become traditional at such meetings the faculty was drawn from an international roster ofleaders in the field of inflammatory bowel disease and gastroenterology. The chapters of the proceedings provide a timely, up-to-date review of the major issues, including those within the realm of basic science and others dealing with clinical problems. The first symposium, 'Basic Research and Clinical Implications', was co-ordinated by John Wallace in association with Stephen Collins and Stephan Targan. The themes of this section were organized under the general topics of predisposing factors (genetics, animal models, infection, permeability, and immune deficits) and the pathophysiology of intestinal inflammation. The second symposium, Trends in Therapy' was organized by Lloyd Sutherland along with Franc;:ois Martin, Robin McLeod and Noel Williams. |
Contents
Genetic factors in animal models of intestinal inflammation | 15 |
Multifactorial control of autoimmune insulindependent | 24 |
from mouse to man | 35 |
Copyright | |
33 other sections not shown
Common terms and phrases
5-aminosalicylic acid acute anastomosis ANCA animal models anorexia antibodies antigen assessment associated autoimmune bacterial cancer chronic Clin Invest clinical Collins SM colon colorectal controlled trial Crohn's disease cyclosporine cytokines develop disease activity dose drugs effects enemas epithelial cells epithelium expression function Gastroenterology gastrointestinal gene genetic growth factor human IBD patients IDDM ileal ileostomy immune Immunol increased induced inflammation inflammatory bowel disease interleukin-1 intestinal epithelial intestinal inflammation intestinal permeability lamina propria leukocyte lymphocytes markers mast cells mechanisms mediators mesalamine mouse mucosal neurons neutrophils NOD mice normal Olsalazine oral pathogenesis patients with Crohn's patients with IBD patients with ulcerative Pentasa peptide Physiol placebo pouchitis prednisone proctocolectomy protein randomized rats receptor rectal relapse remission response risk role SASP Scand J Gastroenterol small intestine smoking smooth muscle specific spontaneous stoma sulfasalazine surgery surgical susceptibility symptoms therapy tissue transgenic treatment ulcerative colitis